Sign in

MBOT on Nasdaq

Microbot Medical Inc.

Microbot Medical Inc. is an American surgical and medical instruments and apparatus company.2 It is headquartered in Hingham, United States.2 Its shares trade on Nasdaq under the symbol MBOT.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Profusa, Inc., Sigyn Therapeutics, Inc. or Fractyl (United States), or pick any stock.

  • TickerMBOT on Nasdaq2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersHingham, United States2
  • Incorporated inDE3
  • Business address25 Recreation Park Dr Suite 108, Hingham, Ma 020433
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300AEUNO16KTJXD722
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 21682892

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$14.7M in 2025+104% since 2019
-$15.0M-$10.0M-$5.0M02019: -$7.2M-$7.2M20192020: -$9.1M-$9.1M2020+26%2021: -$11.4M-$11.4M2021+25%2022: -$13.3M-$13.3M2022+17%2023: -$9.9M-$9.9M2023−26%2024: -$11.6M-$11.6M2024+18%2025: -$14.7M-$14.7M2025+27%
Net income456789-$13.1M in 2025+81% since 2019
-$15.0M-$10.0M-$5.0M02019: -$7.2M-$7.2M20192020: -$9.2M-$9.2M2020+27%2021: -$11.3M-$11.3M2021+23%2022: -$13.2M-$13.2M2022+16%2023: -$10.7M-$10.7M2023−18%2024: -$11.4M-$11.4M2024+7%2025: -$13.1M-$13.1M2025+15%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development, net-$6.3M-$6.6M
Sales, general and administrative-$8.5M-$5.0M
Operating loss-$14.7M-$11.6M
Financing income, net$1.3M$182.0K
Other income$316.0K
Net loss-$13.1M-$11.4M
Basic net loss per share-$0.29-$0.73
Diluted net loss per share-$0.29-$0.73
Basic weighted average common shares outstanding45.8M shares15.6M shares
Diluted weighted average common shares outstanding45.8M shares15.6M shares

Compare Microbot Medical Inc. with another company

Corporate structure

Microbot Medical Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Microbot Medical Inc.

  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G on Microbot Medical Inc., latest Jan 23, 2026 (5 filings since Jan 10, 2025)
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Microbot Medical Inc., latest Oct 31, 2025 (2 filings since Jul 29, 2025)
  • CVI Investments, Inc. Filed SCHEDULE 13G/A on Microbot Medical Inc., latest May 12, 2025 (2 filings since Jan 13, 2025)
  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on Microbot Medical Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • Microbot Medical Inc. Hingham, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Microbot Medical Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$724.0K9 Dec 31, 2025$664.0K9 Dec 31, 2024+9.0%
Accumulated depreciation$631.0K9 Dec 31, 2025$584.0K9 Dec 31, 2024+8.0%
Property and equipment, net$93.0K9 Dec 31, 2025$80.0K9 Dec 31, 2024+16.2%
Operating-lease assets (leased space)$833.0K9 Dec 31, 2025$132.0K9 Dec 31, 2024+531.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.9M9 Dec 31, 2025$3.1M9 Dec 31, 2024+25.6%
Marketable securities, current$74.7M9 Dec 31, 2025$2.4M9 Dec 31, 2024+3069.8%

Inventory

ItemLatestA year beforeChange
Inventory, total$584.0K9 Dec 31, 2025
Work in process$168.0K9 Dec 31, 2025

Properties, in its own words

Microbot’s U.S.-based employees currently either work remotely or at leased premises in the suburbs of Boston, Massachusetts of approximately 300 square feet. Microbot also occupies facilities in premises of approximately 6,975 square feet at 6 Hayozma St., Yokneam, P.O.B. 242, Israel. These facilities are expected to provide the space and infrastructure necessary to accommodate its commercial and business development work based on its current operating plan. Microbot does not own any real property.

Item 2 of the 10-K filed Mar 26, 2026.12

Leadership

Who has led Microbot Medical Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Martin M. McGlynn2006–2016
  2. Harel Gadot2016–now

Chair

  1. Harel Gadot2016–now

President

  1. Martin M. McGlynn2006–2016
  2. Harel Gadot2017–now

Chief financial officer

  1. Rodney Kb Young2006–2013
  2. Gregory T. Schiffman2014–2016
  3. David Ben Naim2016–2018
  4. Rachel Vaknin2022–now

Chief operating officer

  1. Ann Tsukamoto2007–2009
  2. Yehezkel Himelfarb2016–2017
2010201520202025
Board members and other officers (24)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorDavid Wilson named Jan 22, 2025 to Sep 30, 202545

Former names

  • STEMCELLS INCDec 5, 2000 to Nov 15, 20163
  • CYTOTHERAPEUTICS INC/DEFeb 14, 1994 to May 15, 20003

Timeline

  1. Oct 6, 20268-K Regulation FD disclosure46
  2. Sep 28, 20268-K Regulation FD disclosure47
  3. Aug 11, 20268-K Regulation FD disclosure48
  4. Aug 7, 20268-K Entered a material agreement; Executive or director change49
  5. Jul 21, 20268-K Regulation FD disclosure50
  6. Jul 7, 20268-K Regulation FD disclosure; Other events51
  7. Jun 30, 20268-K Regulation FD disclosure; Other events52
  8. Jun 25, 20268-K Regulation FD disclosure53
  9. Jun 23, 20268-K Regulation FD disclosure; Other events54
  10. Jun 16, 20268-K Regulation FD disclosure55
  11. Jun 9, 20268-K Regulation FD disclosure; Other events56
  12. Jun 2, 20268-K Regulation FD disclosure; Other events57
  13. Nov 30, 2016New chief executive Harel Gadot becomes CEO13
  14. Mar 31, 2006New chief executive Martin M. McGlynn becomes CEO14
  15. Aug 2, 1988Founded Microbot Medical Inc. is founded2

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.07) a share, on Nov 12, 2025.58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

400 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 183 major events, 57 insider forms, 11 large holders, 5 private raises, 124 other. The latest 20:

  1. Oct 6, 20268-K EDGAR
  2. Sep 28, 20268-K EDGAR
  3. Aug 11, 20268-K EDGAR
  4. Aug 11, 202610-Q EDGAR
  5. Aug 7, 20268-K EDGAR
  6. Jul 21, 20268-K EDGAR
  7. Jul 7, 20268-K EDGAR
  8. Jun 30, 20268-K EDGAR
  9. Jun 25, 20268-K EDGAR
  10. Jun 23, 20268-K EDGAR
  11. Jun 16, 20268-K EDGAR
  12. Jun 9, 20268-K EDGAR
  13. Jun 2, 20268-K EDGAR
  14. May 26, 20268-K EDGAR
  15. May 15, 20268-K EDGAR
  16. May 14, 20268-K EDGAR
  17. May 13, 202610-Q EDGAR
  18. May 5, 20268-K EDGAR
  19. Apr 30, 20268-K EDGAR
  20. Apr 22, 20268-K EDGAR

The 400 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Harel Gadot53$520.2K$1.2M63
2024Simon Sharon64$241.5K$539.4K63
2024Juan Diaz-Cartelle48$350.0K$376.5K63
2024Rachel Vaknin46$162.8K$363.2K63
2023CEOPresident & Chairman$372.5K$1.3M63
2023CTO and General Manager$195.9K$469.9K63
2023CFO$139.6K$289.5K63
2023CMO$14.8K$15.5K63

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$55.6M 2024–2025
Money received by yearMoney received by year, 2024–2025: $55.6M in all. Private raises (Form D) $55.6M.$0$20M$40M$60M2024 · Private raises (Form D): $1.8M20242025 · Private raises (Form D): $53.8M2025
Figures by year
YearPrivate raises (Form D)Total
2025$53.8M$53.8M
2024$1.8M$1.8M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Sep 16, 2025Raised $25.2 million in a private offering of securities45 Form D: 1 investor so far Form D
  2. Feb 11, 2025Raised $13 million in a private offering of equity64 Form D: 5 investors so far Form D
  3. Jan 10, 2025Raised $8.6 million in a private offering of equity65 Form D: 5 investors so far Form D
  4. Jan 7, 2025Raised $7 million in a private offering of equity66 Form D: 5 investors so far Form D
  5. Jun 3, 2024Raised $1.8 million in a private offering of equity67 Form D: 3 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 70. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC2,906,810$5.7M0.0%−2,715
Mitsubishi UFJ Asset Management Co., Ltd.1,268,453$2.5M0.0%New
BlackRock, Inc.902,411$1.8M0.0%+45,013
Geode Capital Management, LLC836,271$1.6M0.0%+75,440
UBS Group AG806,847$1.6M0.0%−10,098
DNB Asset Management AS677,498$1.3M0.0%No change
Stifel Financial Corp589,924$1.2M0.0%+16,849
Marshall Wace, Llp541,963$1.1M0.0%+60,918
Susquehanna International Group, Llp525,827$1.0M0.0%−398,480
Vanguard Fiduciary Trust Co431,033$840.5K0.0%+30,808
State Street Corp303,569$592.0K0.0%No change
AlphaCentric Advisors LLC250,000$487.5K0.4%+50,000
Northern Trust Corp147,530$287.7K0.0%+4,170
Group One Trading LLC106,429$207.5K0.0%+59,866
Jane Street Group, LLC106,134$207.0K0.0%−35,407
American Century Companies Inc93,314$182.0K0.0%+80,896
Millennium Management LLC86,302$168.3K0.0%−368,444
Invesco Ltd.52,201$101.8K0.0%+22,781
Charles Schwab Investment Management Inc50,000$97.5K0.0%No change
Vontobel Holding Ltd.48,088$93.8K0.0%No change
Envestnet Asset Management Inc47,426$92.5K0.0%+2,804
Bridgeway Capital Management, LLC44,300$86.4K0.0%−50,000
Cetera Investment Advisers43,812$85.4K0.0%+1,400
Lazari Capital Management, Inc.36,600$71.4K0.0%+13,345
Hilltop Holdings Inc.35,764$69.7K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Microbot Medical Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMicrobot Medical Inc.1
  • CIK0000883975
  • Employer ID (EIN)94-307812512
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company12
  • Incorporated inDelaware12
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address25 Recreation Park Dr Suite 108, Hingham, MA 020431
  • Phone908-938-55611
  • Shares outstanding67,164,801 as of Aug 11, 202611
  • Public float$95.7M as of Jun 30, 202512
  • AuditorBrightman Almagor Zohar & Co., Tel Aviv, Israel PCAOB ID 1197; no auditor attestation of internal control over financial reporting12
  • On EDGAR sinceFeb 14, 19941
  • Filings1,522 in all: 8-K (461), 4 (435), 10-Q (91), 424B3 (56), 424B5 (44), SC 13G/A (41), 3 (33), DEF 14A (30)1
    All 51 form types

    10-K (27), SC 13G (25), EFFECT (19), UPLOAD (19), CORRESP (17), DEFA14A (16), S-3 (16), 4/A (14), S-1/A (14), 10-K/A (13), SC 13D/A (13), 8-K/A (12), PRE 14A (12), S-3/A (12), S-8 (12), POS AM (11), D (10), S-1 (10), SC 13D (7), 10-Q/A (6), 5 (5), SCHEDULE 13G/A (5), SCHEDULE 13G (4), 10-K405 (3), 3/A (3), NT 10-K (3), 424B2 (2), ARS (2), CT ORDER (2), NT 10-Q (2), REGDEX (2), RW (2), 10-K405/A (1), 424B7 (1), 8-A12G (1), AW (1), DEFM14A (1), DEFR14A (1), DFAN14A (1), FWP (1), PREM14A (1), REGDEX/A (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Apr 29, 2025
    Latest 8-K (8-K) Oct 6, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, Par value $0.01MBOTNASDAQ

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).12

Risk factors and legal proceedings

The risks Microbot Medical Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 47 risks under these headings, as written.12

  • Risks Relating to Microbot’s Financial Position and Need for Additional Capital
  • Through December 31, 2025, Microbot has not recognized any revenues, and cannot make any assurances of generating significant revenues in the future. It is expected to continue to incur significant operating losses for the foreseeable future. The Company may never become profitable or, if achieved, be able to sustain profitability.
  • Microbot has a limited operating history as a commercial-stage company since it ceased primarily being a research and development-stage company, which may make it difficult to evaluate the prospects for the Company’s future viability.
  • Microbot expects to need additional funding to continue to transition to a profitable commercial enterprise and build a sustainable business model. If Microbot is unable to raise capital, it could be forced to delay, reduce or eliminate its product development programs or commercialization efforts or future product development programs.
  • Risks Relating to the Development and Commercialization of Microbot’s Products
  • Microbot’s business depends heavily on the success of its sole product, the LIBERTY® Endovascular Robotic Surgical System. If Microbot is unable to commercialize the LIBERTY® Endovascular Robotic Surgical System, or experiences significant delays in doing so, Microbot’s business will be materially harmed.
  • If the commercial opportunity for the LIBERTY® Endovascular Robotic Surgical System and any other commercial products that may be developed by Microbot is smaller than Microbot anticipates, Microbot’s future revenue from the LIBERTY® Endovascular Robotic Surgical System and such other products will be adversely affected and Microbot’s business will suffer.
  • Customers will be unlikely to buy the LIBERTY® Endovascular Robotic Surgical System or any other product candidates unless Microbot can demonstrate that they can be produced for sale to consumers at attractive prices.
  • If Microbot is not able to both obtain and maintain adequate levels of third-party reimbursement for procedures involving the LIBERTY® Endovascular Robotic Surgical System or any other of its product candidates after they are approved for marketing and launched commercially, it would have a material adverse effect on Microbot’s business.
  • Unsuccessful studies, trials or procedures relating to product candidates under development or that we may develop, or applications for such candidates, could have a material adverse effect on our prospects.
  • The results of Microbot’s research and development efforts are uncertain and there can be no assurance of the commercial success of Microbot’s future product applications or candidates.
  • Microbot may not meet its development and commercialization objectives in a timely manner or at all.
The other 37 risks
  • Microbot’s ability to expand its technology platforms for other uses may be limited.
  • Microbot does not know whether any data submitted with any future 510(k) application will satisfy all FDA requirements to support clearance of any future product candidate of Microbot, which would create uncertainty for Microbot as well as the possibility of increased product development costs and time to market for any such product candidate.
  • Microbot will depend upon the ability of third parties, including contract research organizations, collaborative academic groups, future clinical trial sites and investigators, to conduct or to assist the Company in conducting clinical trials for any future product applications and candidates, if such trials become necessary.
  • Our research and development program is dependent on the availability of certain components from suppliers, the delay in delivery of which could materially adversely affect our ongoing development and ability to manufacture and package devices in the timeframes currently expected.
  • Microbot has relied on, and intends to continue to rely on, third-party manufacturers to produce its products and product candidates.
  • If Microbot’s products and product candidates are not considered to be a safe and effective alternative to existing technologies, Microbot will not be commercially successful.
  • Microbot may be subject to penalties and may be precluded from marketing its products and product candidates if Microbot fails to comply with extensive governmental regulations.
  • Microbot products may in the future be subject to mandatory product recalls that could harm its reputation, business and financial results.
  • If LIBERTY® or other of Microbot’s future commercialized products cause or contribute to a death or a serious injury, Microbot will be subject to Medical Device Reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.
  • Microbot could be exposed to significant liability claims if Microbot is unable to obtain insurance at acceptable costs and adequate levels or otherwise protect itself against potential product liability claims.
  • If Microbot fails to retain certain of its key personnel and attract and retain additional qualified personnel, Microbot might not be able to pursue its growth strategy effectively.
  • Our profitability may be negatively impacted by inflation in the cost of labor, materials, and services.
  • Risks Relating to International Business
  • If Microbot fails to obtain regulatory clearances in other countries for LIBERTY® or any other future product candidates, Microbot will not be able to commercialize these products or product candidates in those countries.
  • Microbot operations in international markets involve inherent risks that Microbot may not be able to control.
  • Microbot’s financial results may be affected by fluctuations in exchange rates and Microbot’s current currency hedging strategy may not be sufficient to counter such fluctuations.
  • Risks Relating to Microbot’s Intellectual Property
  • Intellectual property litigation and infringement claims could cause Microbot to incur significant expenses or prevent Microbot from selling certain of its product candidates.
  • If Microbot or TRDF are unable to protect the patents or other proprietary rights relating to Microbot’s product candidates, or if Microbot infringes on the patents or other proprietary rights of others, Microbot’s competitiveness and business prospects may be materially damaged.
  • Dependence on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may result in Microbot’s payment of significant monetary damages or impact offerings in its product portfolios.
  • Risks Relating to Operations in Israel
  • Existing and historical risks relating to our operations in Israel are being exacerbated by the current military actions and operations, and related activities, following the U.S.-Israel joint attach on Iran.
  • Microbot has facilities located in Israel, and therefore, political conditions in Israel may affect Microbot’s operations and results.
  • Political relations could limit Microbot’s ability to sell or buy internationally.
  • Israel’s economy may become unstable.
  • Exchange rate fluctuations between the U.S. dollar and the NIS currencies may negatively affect Microbot’s operating costs.
  • Funding and other benefits provided by Israeli government programs may be terminated or reduced in the future and the terms of such funding may have an impact on future corporate decisions.
  • Some of Microbot’s employees are obligated to perform military reserve duty in Israel.
  • It may be difficult to enforce a non-Israeli judgment against Microbot or its officers and directors.
  • Risks Relating to Microbot’s Securities, Governance and Other Matters
  • If we fail to comply with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
  • We do not expect to pay cash dividends on our common stock.
  • Anti-takeover provisions in the Company’s charter and bylaws under Delaware law may prevent or frustrate attempts by stockholders to change the board of directors or current management and could make a third-party acquisition of the Company difficult.
  • General Risks
  • Political, social and geopolitical conditions can adversely affect our business.
  • Political uncertainty may have an adverse impact on our operating performance and results of operations.
  • Raising additional capital may cause dilution to the Company’s investors, restrict its operations or require it to relinquish rights to its technologies or product candidates.
  • Microbot operates in a competitive industry and if its competitors have products that are marketed more effectively or develop products, treatments or procedures that are similar, more advanced, safer or more effective, its commercial opportunities will be reduced or eliminated, which would materially harm its business.
  • Information technology failures and data security breaches could harm our business.
  • Our business strategy in part relies on identifying, acquiring and developing complementary technologies and products, which entails risks which could negatively affect our business, operations and financial condition.
  • The market price for our common stock may be volatile.
  • The issuance of shares upon exercise of outstanding warrants and options could cause immediate and substantial dilution to existing stockholders.

Legal proceedings

On June 17, 2025, the Company received a demand letter from legal counsel representing a former employee in connection with an employment-related matter. On December 3, 2025, the Company received a charge filed by the former employee with the Massachusetts Commission Against Discrimination and Equal Employment Opportunity Commission, alleging discrimination and retaliation. On January 16, 2026, the Company filed a position statement responding to same and challenging the merits of the charge in total. Based on its initial assessment, the Company believes the allegations lack merit and intends to defend against them.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.

The opening of Item 3, Legal Proceedings.12

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67